Compare Amylx Pharmaceuticals Inc (AMLX) vs TJX Companies Inc (TJX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs TJX Companies Inc — how do they compare? Amylx Pharmaceuticals Inc trades at $23.54 (market cap $2.64B), while TJX Companies Inc trades at $152.64 (market cap $172.05B). The key difference: TJX Companies Inc is far larger — about 65.2× Amylx Pharmaceuticals Inc's market cap, and TJX Companies Inc pays a 1.23% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | TJX | |
|---|---|---|
Market Cap | $2.64B | $172.05B |
Sector | Health | Consumer Cyclical |
52-Week High | $24.19 | $168.41 |
52-Week Low | $7.82 | $132.62 |
Enterprise Value | $2.39B | $180.65B |
Dividend Yield | — | 1.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $23.61, up 4.15% today, with strong analyst support (91% buy ratings) and a $30 consensus price target. The stock shows bullish technical momentum despite negative profitability metrics (ROE -74.73%, ROA -66.25%). Recent Q2 2026 earnings missed expectations, but the company maintains $250.8M cash runway into 2028, supporting its pivotal Phase 3 LUCIDITY trial readout expected August-September 2026.
The investment thesis hinges on successful avexitide clinical outcomes, with potential 2027 launch offering significant upside. Key risks include ongoing financial losses, clinical trial execution, and competitive pressures. Current valuation at 11.02x book value appears stretched given negative earnings, making positive trial results critical for justifying premium pricing.
TJX trades at $154.17, down 2.92% over the past day, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $1.19 exceeding the $1.02 estimate. Revenue grew to $56.36 billion in 2025, and net income margin improved to 8.63%. Analysts maintain a bullish consensus with an average price target of $181.80, citing momentum and value prospects.
The outlook for TJX remains positive driven by consistent earnings outperformance and robust profitability metrics like a 61.25% ROE. Key risks include competitive pressures in discount retail and sensitivity to consumer spending trends. The stock offers upside to analyst targets but faces near-term technical headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About TJX Companies Inc
TJX is a leading off-price retailer of apparel, home fashions, and other merchandise. It sells a variety of branded goods, opportunistically buying inventory from a network of over 21,000 vendors worldwide. TJX targets undercutting conventional retailers' regular prices by 20%-60%, capitalizing on a flexible merchandising network, relatively low-frills stores, and a treasure-hunt shopping experience to drive margins and inventory turnover. TJX derived 79% of fiscal 2022 revenue from the United States, with 11% from Europe (mostly the United Kingdom and Germany), 9% from Canada, and the remainder from Australia. The company operated 4,689 stores at the end of fiscal 2022 under the T.J. Maxx, T.K. Maxx, Marshalls, HomeGoods, Winners, Homesense, Winners, and Sierra banners.
Read more on TJX →
